Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-745bb68f8f-cphqk Total loading time: 0 Render date: 2025-01-11T17:49:50.716Z Has data issue: false hasContentIssue false

43 - Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development

from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development

Published online by Cambridge University Press:  03 March 2022

By
Maria C. Carrillo ,
Emily A. S. Meyers  and
Heather M. Snyder
Edited by
Jeffrey Cummings ,
Jefferson Kinney  and
Howard Fillit
Jeffrey Cummings
Affiliation:
University of Nevada, Las Vegas
Jefferson Kinney
Affiliation:
University of Nevada, Las Vegas
Howard Fillit
Affiliation:
Alzheimer’s Drug Discovery Foundation
Get access

Summary

Alzheimer’s disease (AD) is a public health challenge that grows in urgency every year. As the world’s largest dedicated voluntary health organization to AD and related dementia (ADRD), the Alzheimer’s Association has a vision of a world without AD and ADRD. In addition to providing care and support in communities across the United States and actively pursuing advocacy for federal research support and community needs,it is committed to advancing vital research toward methods of treatment, prevention, and a cure. In addition to financial support to researchers worldwide, it promotes the sharing of knowledge and data, gathering key stakeholders form the field, including academia, federal, non-profit and industry to advance research (such as through the Alzheimer’s Association International Conference) and accelerating clinical trial research though Alzheimer’s Association TrialMatc. The Association’s funding expands the full spectrum of research, with focused funding on drug development and early-phase human trials.

Keywords

Alzheimer’s diseaseAlzheimer’s AssociationDementiaDrug DevelopmentClinical trialsPart the CloudPreventionNonprofitGAAINAlzheimer’s Impact Movement
Type
Chapter
Information
Alzheimer's Disease Drug Development
Research and Development Ecosystem
 , pp. 486 - 495
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020; 16: 391–460.Google Scholar
Alzheimer’s Disease International. World Alzheimer Report 2015: The Global Impact of Dementia. London: Alzheimer’s Disease International; 2015.Google Scholar
Jack, CR, Jr., Albert, MS, Knopman, DS, et al. Introduction to the recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 257–62.CrossRefGoogle Scholar
Petersen, RC, Lopez, O, Armstrong, MJ, et al. Practice guideline update summary: mild cognitive impairment. Neurology 2018; 90: 126–35.CrossRefGoogle ScholarPubMed
Ward, A, Tardiff, S, Dye, C, Arrighi, HM. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Disord Extra 2013; 3: 320–32.Google Scholar
Mitchell, AJ, Shiri-Feshki, M. Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119: 252–65.Google Scholar
Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 280–92.Google Scholar
Albert, MS, DeKosky, ST, Dickson, D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270–9.CrossRefGoogle ScholarPubMed
McKhann, GM, Knopman, DS, Chertkow, H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263–9.Google Scholar
Karlawish, J, Jack, CR, Jr., Rocca, WA, Snyder, HM, Carrillo, MC. Alzheimer’s disease: the next frontier – special report 2017. Alzheimers Dement 2017; 13: 374–80.Google Scholar
Jack, CR, Jr., Bennett, DA, Blennow, K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016; 87: 539–47.CrossRefGoogle ScholarPubMed
Jack, CR, Jr., Bennett, DA, Blennow, K, et al. NIA–AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535–62.Google Scholar
Alzheimer’s Association. The Tau Pipeline Enabling Program (T-PEP). Available at: www.alz.org/research/for_researchers/grants/types-of-grants/partnership_funding_programs/the_tau_pipeline_enabling_program_(t-pep)_(2) (accessed July 24, 2021).Google Scholar
Johnson, KA, Minoshima, S, Bohnen, NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med 2013; 54: 476–90.CrossRefGoogle Scholar
Mattsson, N, Andreasson, U, Persson, S, et al. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement 2013; 9: 251–61.Google Scholar
Carrillo, MC, Blennow, K, Soares, H, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium. Alzheimers Dement 2013; 9: 137–40.CrossRefGoogle ScholarPubMed
Shaw, LM, Arias, J, Blennow, K, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. Alzheimers Dement 2018; 14: 1505–21.Google Scholar
National Institute on Aging. Together we make the difference: national strategy for recruitment and participation in Alzheimer’s and related dementias clinical research. Available at: www.nia.nih.gov/research/recruitment-strategy (accessed July 20, 2021).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×